HR
TCRR

Howe & Rusling’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Howe & Rusling’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50
Closed – – 1228
2022
Q2 		$0 Buy
+50
New +$123 ﹤0.01% 1194

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Howe & Rusling's TCRR Position: Q3 2022 in Review

Howe & Rusling sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 50 shares.

Howe & Rusling first reported a position in TCRR in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • Howe & Rusling reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 50 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022.
  • Howe & Rusling first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Howe & Rusling's TCR2 Therapeutics Inc. Common Stock position peaked at $0 in Q2 2022.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.